Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Irwin

Showing results (41-50 of 161) with videos related to

Pageof 17
Sort By:
Diabetes, Obesity & Metabolism|June 9, 2021
Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed miceShruti Mohan, Peter R Flatt, Nigel Irwin, et al.
The Journal of Endocrinology|January 25, 2020
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetesNeil Tanday, Peter R Flatt, Nigel Irwin, et al.
Biological Chemistry|August 10, 2020
Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytesAndrew English, Sarah L Craig, Peter R Flatt, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|June 28, 2019
Effects of 2 Novel PYY(1-36) Analogues, (P<sup>3</sup>L<sup>31</sup>P<sup>34</sup>)PYY(1-36) and PYY(1-36)(Lys<sup>12</sup>PAL), on Pancreatic Beta-Cell Function, Growth, and SurvivalRyan A Lafferty, Victor A Gault, Peter R Flatt, et al.
The Journal of Endocrinology|October 12, 2012
Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal miceNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
The Journal of Endocrinology|August 6, 2013
Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptorGuillaume Mabilleau, Aleksandra Mieczkowska, Nigel Irwin, et al.
The Journal of Biological Chemistry|October 30, 2013
A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed miceVictor A Gault, Vikas K Bhat, Nigel Irwin, et al.
Plos One|August 13, 2015
Gastric inhibitory polypeptide (GIP) is selectively decreased in the roux-limb of dietary obese mice after RYGB surgeryJiaqiang Zhou, Zheng Hao, Nigel Irwin, et al.
Bone|June 18, 2016
High fat-fed diabetic mice present with profound alterations of the osteocyte networkGuillaume Mabilleau, Rodolphe Perrot, Peter R Flatt, et al.
Biochemical Pharmacology|December 6, 2020
The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xeninSarah L Craig, Victor A Gault, Peter R Flatt, et al.
Pageof 17

Showing results (41-50 of 161) with videos related to

Sort By:
Pageof 17
Diabetes, Obesity & Metabolism|June 9, 2021
Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed miceShruti Mohan, Peter R Flatt, Nigel Irwin, et al.
The Journal of Endocrinology|January 25, 2020
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetesNeil Tanday, Peter R Flatt, Nigel Irwin, et al.
Biological Chemistry|August 10, 2020
Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytesAndrew English, Sarah L Craig, Peter R Flatt, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|June 28, 2019
Effects of 2 Novel PYY(1-36) Analogues, (P<sup>3</sup>L<sup>31</sup>P<sup>34</sup>)PYY(1-36) and PYY(1-36)(Lys<sup>12</sup>PAL), on Pancreatic Beta-Cell Function, Growth, and SurvivalRyan A Lafferty, Victor A Gault, Peter R Flatt, et al.
The Journal of Endocrinology|October 12, 2012
Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal miceNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
The Journal of Endocrinology|August 6, 2013
Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptorGuillaume Mabilleau, Aleksandra Mieczkowska, Nigel Irwin, et al.
The Journal of Biological Chemistry|October 30, 2013
A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed miceVictor A Gault, Vikas K Bhat, Nigel Irwin, et al.
Plos One|August 13, 2015
Gastric inhibitory polypeptide (GIP) is selectively decreased in the roux-limb of dietary obese mice after RYGB surgeryJiaqiang Zhou, Zheng Hao, Nigel Irwin, et al.
Bone|June 18, 2016
High fat-fed diabetic mice present with profound alterations of the osteocyte networkGuillaume Mabilleau, Rodolphe Perrot, Peter R Flatt, et al.
Biochemical Pharmacology|December 6, 2020
The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xeninSarah L Craig, Victor A Gault, Peter R Flatt, et al.
Pageof 17